# Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

> **NCT03325595** · PHASE1 · COMPLETED · sponsor: **Aelis Farma** · enrollment: 40 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** AEF0117
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03325595
- **Lead sponsor:** Aelis Farma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-06
- **Primary completion:** 2018-02-26
- **Final completion:** 2018-02-26
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03325595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03325595, "Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03325595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*